Roger S McIntyre

Roger S McIntyre, MD, FRCPC

Dr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and the Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada.

Dr. McIntyre was named by Thomson Reuters in 2014 as one of “The World’s Most Influential Scientific Minds”. This distinction is bestowed upon researchers who publish the most highly cited articles in a variety of scientific fields during the previous decade.

Dr. McIntyre is extensively involved in medical education.  He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto’s Department of Psychiatry and has been selected for the joint Canadian Psychiatric Association (CPA)/Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.
 
Dr. McIntyre is the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the CANMAT guidelines for the treatment of Depressive Disorders and Bipolar Disorders. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders.

Dr. McIntyre completed his medical degree at Dalhousie University and completed his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.
Dr. McIntyre is involved in multiple research endeavours which aim to characterize the association between mood disorders, especially cognitive function and medical comorbidity.  Broadly, his work aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.
Bipolar Disord. 2017 May;19(3):198-213
Soczynska JK, Kennedy SH, Alsuwaidan M, Mansur RB, Li M, McAndrews MP, Brietzke E, Woldeyohannes HO, Taylor VH, McIntyre RS
Rev Neurosci. 2017 May 08;:
Rios AC, Maurya PK, Pedrini M, Zeni-Graiff M, Asevedo E, Mansur RB, Wieck A, Grassi-Oliveira R, McIntyre RS, Hayashi MAF, Brietzke E
J Clin Psychopharmacol. 2017 Jun 05;:
McIntyre RS, Lee Y, Zhou AJ, Rosenblat JD, Peters EM, Lam RW, Kennedy SH, Rong C, Jerrell JM
Dialogues Clin Neurosci. 2017 Mar;19(1):27-36
Subramaniapillai M, Carmona NE, Rong C, McIntyre RS
Pharmacol Res. 2017 May 10;:
Rong C, Lee Y, Carmona NE, Cha DS, Ragguett RM, Rosenblat JD, Mansur RB, Ho RC, McIntyre RS
Schizophr Res. 2017 May 08;:
Lee BS, McIntyre RS, Gentle JE, Park NS, Chiriboga DA, Lee Y, Singh S, McPherson MA
Bipolar Disord. 2017 Mar;19(2):128-134
McIntyre RS, Mansur RB, Lee Y, Japiassú L, Chen K, Lu R, Lu W, Chen X, Li T, Xu G, Lin K
Psychoneuroendocrinology. 2017 Apr 27;81:144-150
Platzer M, Dalkner N, Fellendorf FT, Birner A, Bengesser SA, Queissner R, Kainzbauer N, Pilz R, Herzog-Eberhard S, Hamm C, Hörmanseder C, Maget A, Rauch P, Mangge H, Fuchs D, Zelzer S, Schütze G, Moll N, Schwarz MJ, Mansur RB, McIntyre RS, Reininghaus EZ
J Affect Disord. 2017 Apr 23;218:246-252
Su JA, Cheng BH, Huang YC, Lee CP, Yang YH, Lu ML, Hsu CY, Lee Y, McIntyre RS, Chin Lin T, Chin-Hung Chen V

Pages


 

Head, Mood Disorders Psychopharmacology Unit, UHN
Professor, Departments of Psychiatry and Pharmacology and Toxicology, University of Toronto